Does Cancer Cause Numbness? Symptoms and Causes

Cancer can cause numbness, and it does so through a surprisingly wide range of pathways. A tumor may press directly on a nerve, but just as often the numbness traces back to cancer treatment itself, particularly chemotherapy, radiation, or even newer immunotherapies. The relationship between cancer and numbness is not one story but several, and understanding which mechanism is at work matters because the right response differs in each case.

When a Tumor Presses on a Nerve

The most intuitive way cancer causes numbness is by physically compressing or invading nerve tissue. Tumors growing near the spine, in the pelvis, or in the chest can push against nerve roots or entire nerve bundles called plexuses. The brachial plexus, which runs from the neck into the arm, and the lumbosacral plexus, which serves the lower body, are common sites. As a tumor grows into these areas, the result is often a combination of pain, weakness, and numbness that progresses over time.¹

Metastatic cancer that spreads to the spine poses a particular threat. Tumors in or around the vertebrae can compress the spinal cord, and when that happens, numbness is part of a larger constellation of symptoms. In a landmark review of patients with epidural spinal cord compression from metastatic tumors, pain was the primary symptom in roughly 96% of patients, and more than four in five had motor or sensory deficits or both.² The numbness in these cases tends to start in the legs and move upward, and it frequently arrives alongside trouble walking or controlling the bladder. This scenario calls for urgent medical intervention, not watchful waiting.

Numb Chin Syndrome

One of the more peculiar and underrecognized cancer-related presentations is numb chin syndrome. If you suddenly notice that one side of your chin or lower lip has gone numb for no obvious reason, and you have not recently had dental work or an injury, that warrants a serious look. Numb chin syndrome involves the mental nerve, a branch that supplies sensation to the chin and lower lip. When this nerve is affected by cancer that has spread to the jawbone or nearby structures, the numbness is often the first clue that something systemic is going on.³

This syndrome has been documented in patients with breast cancer, lymphoma, lung cancer, and other malignancies. A case report of metastatic lung cancer presenting initially with chin numbness illustrates the point: the numbness itself was not the dangerous part, but it was the canary in the coal mine.⁴ Doctors and dentists sometimes miss this because isolated chin numbness seems so minor. The clinical message is clear: unexplained numbness in the chin or jaw, particularly in someone with a cancer history, deserves imaging and further workup rather than reassurance.

Chemotherapy-Induced Peripheral Neuropathy

For many cancer patients, the numbness they experience has nothing to do with the tumor itself and everything to do with their treatment. Chemotherapy-induced peripheral neuropathy, usually shortened to CIPN, is one of the most common and frustrating side effects of cancer treatment. It presents primarily as a sensory problem: tingling, burning, or numbness in the hands and feet, sometimes with motor or autonomic changes on top of that. Six major classes of chemotherapy drugs are known to damage peripheral nerves, including platinum-based agents, taxanes, vinca alkaloids, proteasome inhibitors, immunomodulatory drugs, and epothilones.⁵

The pattern of CIPN is distinctive. It almost always starts in the fingertips and toes and works its way inward, following a “glove-and-stocking” distribution. Some patients notice it during treatment and find it resolves once chemotherapy ends. Others are left with numbness that persists for months or years, and a subset develop chronic neuropathy that never fully reverses. The severity depends partly on which drug is used, the cumulative dose, and individual vulnerability. This long tail of nerve damage is a major quality-of-life concern for cancer survivors.

Radiation and Surgical Nerve Damage

Radiation therapy saves lives, but it can leave lasting marks on nearby nerves. Radiation-induced brachial plexopathy is the best-studied example, occurring most often after treatment for breast or lung cancer. What makes this particularly tricky is the delay: symptoms like tingling, numbness, and progressive weakness in the arm may not appear until months or even years after the last radiation session. Once it sets in, the damage from fibrosis and demyelination around the nerve fibers tends to worsen gradually rather than stabilize.⁶ Case reports describe patients presenting a decade or more after treatment with worsening numbness and muscle wasting in the affected arm.⁷

Surgery carries its own risks. During operations to remove tumors, nerves in the area may be cut, stretched, or damaged incidentally. Breast cancer surgery is a well-documented example: the intercostobrachial nerve, which supplies sensation to the inner upper arm, is sometimes resected or injured during mastectomy or lymph node dissection. This can leave patients with lasting numbness in the armpit and upper arm area, and in some cases the numbness is accompanied by neuropathic pain.⁸ This is generally not a sign of cancer recurrence, but it can be distressing and persistent.

Immunotherapy and the Immune System’s Friendly Fire

Immune checkpoint inhibitors have transformed oncology over the past decade, but they work by unleashing the immune system, and sometimes it attacks the body’s own tissues in the process. Neuropathy is one of the recognized immune-related side effects, though it remains uncommon. In one study of over 900 patients treated with checkpoint inhibitors, about 2% developed peripheral nervous system problems, including polyneuropathy, cranial nerve damage, and small-fiber neuropathy.⁹ Patients may develop numbness and tingling in the limbs, sometimes alongside weakness and pain, usually within the first few cycles of treatment.¹⁰

The good news is that immunotherapy-related neuropathy often responds to treatment. Stopping or pausing the checkpoint inhibitor and adding immunosuppressive medication leads to meaningful improvement in many patients.¹¹ The clinical challenge is recognizing the pattern quickly. Because immunotherapy-related neuropathy can look a lot like CIPN or tumor-related nerve damage, doctors need to piece together the timing and clinical details carefully to identify the cause and start the right treatment.

Blood Cancers and Nerve Damage

Blood cancers have their own relationship with numbness that differs from solid tumors. Multiple myeloma, a cancer of plasma cells in the bone marrow, has long been associated with peripheral neuropathy. The abnormal proteins these cancer cells produce can directly damage nerves, separate from any treatment effect.¹² Related conditions like AL amyloidosis and lymphoplasmacytic lymphoma can do the same, each with somewhat different patterns of nerve involvement.¹³

A study comparing untreated multiple myeloma patients to those with AL amyloidosis found that significant neuropathy was present in roughly 18% of myeloma patients and 48% of amyloidosis patients before any treatment had begun.¹⁴ This is an important point: when someone with one of these cancers develops numbness in their hands or feet, it is not necessarily a side effect of their drug regimen. The cancer itself may be responsible. Untangling these contributions matters because the treatment approach for disease-related neuropathy and drug-related neuropathy can diverge considerably.

Paraneoplastic Syndromes

In rare cases, cancer causes numbness through an even more indirect route. Paraneoplastic neurologic syndromes occur when the immune system, triggered by a tumor, produces antibodies that cross-react with nerve tissue. The tumor itself may be far from the affected nerves. Small cell lung cancer is one of the best-known triggers, and anti-Hu antibodies are among the most frequently identified culprits. These antibodies can cause sensory ganglionopathy, a condition in which the sensory nerve cell bodies themselves are attacked, leading to widespread and often severe numbness that does not follow the typical glove-and-stocking pattern.¹⁵

These syndromes are genuinely rare, but they are clinically significant because the neurological symptoms sometimes appear before the cancer is detected. A person who develops unexplained, rapidly worsening numbness affecting asymmetric parts of the body may end up being diagnosed with cancer only after the antibody testing and imaging prompted by their neurological symptoms. Treating the underlying cancer is the primary approach, though the nerve damage from paraneoplastic syndromes does not always reverse even when the tumor responds to therapy.

Vitamin B12 and Hidden Nutritional Deficits

Cancer and its treatment can create nutritional deficiencies that compound nerve damage. Functional vitamin B12 deficiency, where the body’s B12 levels look normal on a standard blood test but its active metabolites tell a different story, has drawn attention as a potential contributor to neuropathy in cancer patients.¹⁶ Both cancer and neurotoxic chemotherapy drugs increase oxidative stress, which may interfere with B12 metabolism.

A study tracking cancer patients through chemotherapy found that B12 levels dropped substantially over the course of treatment, while markers of B12 dysfunction rose sharply. Increases in one of those markers, methylmalonic acid, significantly predicted worsening neuropathy symptoms.¹⁷ This raises the possibility that monitoring and correcting B12 status during chemotherapy could help reduce the severity of nerve damage, though the evidence is still early enough that it has not become standard practice.

When Numbness Becomes an Emergency

Most cancer-related numbness develops gradually and, while distressing, does not require a trip to the emergency room. But there are exceptions. Cauda equina syndrome, in which a tumor compresses the nerve bundle at the base of the spinal cord, is one of them. The hallmark warning signs are saddle anesthesia (numbness in the area you would sit on a saddle), loss of bladder or bowel control, and rapidly progressing leg weakness. These are considered red-flag symptoms because delayed treatment risks permanent paralysis and incontinence, and many experts recommend surgical decompression as soon as possible.¹⁸

Similarly, spinal cord compression from metastatic disease, as mentioned earlier, demands urgent attention. The practical rule for anyone with cancer: numbness that comes on suddenly, spreads rapidly, or arrives with bladder or bowel changes warrants immediate medical evaluation, not a wait-and-see call to the clinic.

Falls and the Daily Toll of Numbness

Beyond the neurological symptoms themselves, cancer-related numbness carries real-world risks that patients and caregivers often underestimate. When you cannot feel your feet properly, your balance suffers. A study of women with persistent CIPN symptoms found they walked more slowly, took shorter steps, and reported significantly more disability than women without neuropathy. They also had nearly twice the risk of falling.¹⁹ Falls among cancer patients are not a minor inconvenience; they can lead to fractures, hospitalizations, and treatment delays.

Research in breast cancer patients further linked CIPN to significant functional impairments in activities of daily living, with the odds of impairment roughly six times higher in those with neuropathy compared to those without.²⁰ Buttoning a shirt, handling coins, and judging water temperature in the shower all become harder when sensation in the fingers is compromised. These functional losses tend to receive less clinical attention than pain, but they can be just as disruptive to a person’s life.

Treatment Options for Cancer-Related Numbness

Managing cancer-related numbness remains one of oncology’s weak spots. There are no approved drugs to prevent CIPN, and duloxetine is currently the only medication with meaningful evidence supporting its use for treatment.²¹ A randomized trial found that patients taking duloxetine reported a larger decrease in average pain compared with placebo, and about 59% of those on duloxetine reported at least some pain improvement versus 38% on placebo.²² Its effect on numbness specifically is less clear; one analysis noted that roughly 41% of duloxetine patients reported decreased numbness and tingling in the feet, compared to about 23% on placebo, though this difference did not reach statistical significance.²³

For numbness caused by tumor compression, treating the underlying cancer, through surgery, radiation, or systemic therapy, is the primary strategy. If a tumor shrinks or is removed, pressure on the nerve may ease and some sensation can return, though this depends heavily on how long the compression lasted and how much nerve damage accumulated. For radiation-induced or surgical nerve damage, the options are more limited and tend to focus on physical rehabilitation and symptom management rather than reversal.

Cryotherapy as a Preventive Strategy

One of the more promising developments in CIPN prevention involves something remarkably simple: cold. Cryotherapy, typically using frozen gloves and socks during chemotherapy infusions, aims to constrict blood vessels in the hands and feet and reduce the amount of neurotoxic drug that reaches the peripheral nerves. A systematic review and meta-analysis found that cryotherapy significantly reduced the incidence of CIPN during and after chemotherapy, with patients who used it developing sensory neuropathy at roughly two-thirds the rate of those who did not.²⁴

A study in breast cancer patients found that those who received cryotherapy experienced substantially less hand and foot numbness and milder daily neuropathy symptoms compared to a control group, though results for nerve pain and joint discomfort were similar between the two groups.²⁵ The approach is not foolproof and the evidence is still building, but its low cost and minimal side effects make it an appealing option. Some cancer centers now offer frozen gloves and socks as a standard part of infusion sessions, though availability varies widely.

Detecting Small-Fiber Nerve Damage

One reason cancer-related numbness sometimes goes undiagnosed or is dismissed is that conventional nerve tests can miss it. Standard nerve conduction studies measure the electrical signals in large nerve fibers and do a poor job detecting damage to small sensory fibers, which are the ones responsible for much of the tingling and numbness patients describe. Skin biopsy, which measures the density of tiny nerve endings in the upper layer of the skin, has become a valuable alternative. It is far less invasive than traditional nerve biopsy, can be repeated over time to track changes, and is more sensitive for catching the kind of small-fiber damage that chemotherapy and other cancer-related processes cause.²⁶ If your nerve conduction study comes back normal but you still feel numbness and tingling, skin biopsy is worth discussing with your doctor.